PubMed Health⌕ Search

Biomedical subjects

C N Hudson

Publications and source records attributed to C N Hudson.

At least 73 records · Page 4Linked to original sources
PubMed1986

Steroid receptors in human ovarian malignancy. A review of four years tissue collection.

The oestrogen and progestogen receptor status in ovarian cancers from 72 patients was correlated with histological type, primary or secondary origin and peripheral hormone concentrations. Changes occurred in receptor status during malignant transformations of ovarian tissues, with those for oestrogen being found more often, and those for progestogen less often than in non-diseased ovarian fragments. It is suggested that the similarity in sex steroid receptor content between ovarian and breast cancers warrants prospective study of ovarian sex steroid receptor status as a predictive index of survival and response to hormonal therapy in multi-centre clinical trials. Additional data on androgen receptors are also presented.

Adult↗
PubMed1986

A comparison of circulating immune complexes, pregnancy associated beta 1-macroglobulin and galactosyltransferase as tumour markers for ovarian cancer.

Serial blood samples have been obtained from 12 patients with ovarian cancer who were treated by surgery and, generally, chemotherapy or radiotherapy. Some achieved clinical remission, but the majority relapsed after variable time interval. Three potential tumour markers (Circulating Immune Complexes, Pregnancy Associated beta 1-Macroglobulin and Galactosyltransferase) have been studied longitudinally in serum for clinical correlation, predictive value, and biochemical 'lead time' to clinically detectable progression. None of the 3 offered any signal advantage over the others, and each showed an inconsistent relationship to observed disease status, with high levels indicating a poor outlook and the converse not true. Thus, since the 'lead time' is short, and reliability low, none of the compounds can be strongly commended as individual markers for ovarian cancer.

Adenocarcinoma↗
PubMed1985

The value of the monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes.

The use of circulating immune complexes and a commercial monoclonal antibody to ovarian cancer (CA 125 kit) in monitoring progress in patients with ovarian cancer has been assessed. While changes in immune complexes were apparent in some patients with active progression of disease, the marked change in values and linear trend make the use of CA 125 a useful clinical marker.

Antigen-Antibody Complex↗
PubMed1985

The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells.

A radioimmunoassay for the measurement of placental protein 5 (PP5) has been developed using a second antibody-polyethyleneglycol method to separate free from bound ligand. PP5 immunoreactivity was detected in culture media from a cell line derived from a small cell carcinoma of the ovary (SCCWm2). The culture-derived PP5 shares immunological identity with pregnancy and ovarian follicular PP5. Affinity interactions between PP5 and matrices such as heparin or thrombin-Sepharose were similar and independent of the origin of PP5. PP5 was heterogeneous with two forms, a monomer (18k) and dimer (36k) being detected in all biological fluids examined. The dimer was predominant in ovarian follicles and the SCCWm2 cell line, while the monomer predominated in pregnancy serum. The basal rate of PP5 secretion by the SCCWm2 cell line was 0.61AU/24h/10(5) cells. Incubation of cells in the presence of 150mIU Pergonal stimulated PP5 production 20.6 fold and following removal of Pergonal the production rate was maintained at 18.0 times the basal rate. No choriconic gonadotrophin, pregnancy-specific beta 1-glycoprotein, pregnancy associated plasma protein-A or alpha fetoprotein was detected in the culture medium of the SCCWm2 cell line.

Carcinoma, Small Cell↗
PubMed1983

Circulating IgG-specific immune complexes as a potential tumor marker in gynecological malignancies.

A longitudinal study of circulating immune complexes (CIC) of the IgG class has been undertaken in patients presenting for operation of active malignant disease of the female reproductive tract. These values were compared with data obtained during subsequent clinical remission and prior to the clinical diagnosis of relapse. The results showed that irrespective of the site of disease (e.g., ovary, fallopian tube, cervix, endometrium, or vagina) values for CIC were elevated in most patients compared to controls. Postoperative remission status was associated with a significant decrease in values for all tumor sites. Similarly, relapse was associated with elevation of CIC levels to values similar to the preoperative concentrations. It is concluded that CIC may provide a useful biochemical marker of the progression of malignant disease.

Antigen-Antibody Complex↗
PubMed1983

Estrogen and progesterone receptors in human ovarian tumors.

Estrogen and progesterone receptors were measured in cystosols prepared from 32 normal ovaries and 25 benign and 49 malignant ovarian tumors. In normal ovarian tissue, estrogen and progesterone receptors were detected in 22 and 75% of specimens, respectively. Estrogen receptors were present in low concentrations ranging from 2 to 9 fmol/mg cytosol protein. The estrogen receptor content and distribution were similar in benign tumors (20%), but progesterone receptors were significantly decreased in 16% of specimens (P less than 0.001). In malignant ovarian tissues, estrogen receptors were present in 57% of specimens in concentration ranging from 1 to 132 fmol/mg cytosol protein. Of these, 72% of tissues had estrogen-receptor concentrations greater than 10 fmol/mg cytosol protein. The presence of estrogen receptors in ovarian cancer was significantly different from normal ovaries and benign tumor tissues (P less than 0.01). Progesterone receptors were detectable in 29% of ovarian cancer specimens. Estrogen and progesterone receptors were present alone or in combination, in 65% of ovarian cancers. The similarity in sex steroid content between ovarian and breast cancer warrants prospective studies of sex steroid receptor content in ovarian malignancies as a possible predictive index of survival and response to hormone therapy.

Adenocarcinoma, Mucinous↗
PubMed1982

The effect of storage time and molybdate on steroid receptors in gynaecological tissues.

Human female reproductive tract tissues were analysed for estrogen and progestogen receptor content in the presence or absence of sodium molybdate immediately after removal at surgery. Other fractions of the tissue were stored in liquid nitrogen and similarly analysed after 2, 4, 6 and 8 weeks storage. The results showed that at all times the apparent receptor content for both steroids was significantly higher (P less than 0.001) and Kd values were significantly lower (P less than 0.02) in assays carried out with 10 mM molybdate added to the buffer systems. Furthermore, as soon as either whole tissue or tissue cytosol was frozen for storage, receptors were "lost" with values decreasing by approximately 30% for both steroid receptors. However, once frozen in liquid nitrogen tissue receptor content remained stable over the eight weeks of study. It is recommended that laboratories standardize techniques to allow valid comparisons of results.

Cytosol↗
PubMed1981

Victor Bonney Lecture, 1980. Ovarian cancer--a gynaecological disorder?

Ovarian cancer is a disease of great complexity. The diagnosis is commonly delayed and the condition may present in a number of specialties other than gynaecology. Inappropriate primary treatment may seriously compromise the subsequent course. Modern surgical management involves extension beyond the traditional total hysterectomy and bilateral salpingo-oöphorectomy and 'under treatment' by both gynaecologists and general surgeons is common. A multimodal approach is highly desirable, both radiotherapy and chemotherapy having a defined role in management which is largely determined by the histopathology. In spite of modern diagnostic aids the diagnosis is all too frequently only achieved at laparotomy. A plea is made for the transfer of such patients to a gynaecological oncologist for definitive therapy if the primary physician or surgeon is unfamiliar with the full ramifications of the disease or with the range of therapeutic measures, including radical surgery if suitable.

Castration↗
PubMed1981

E-rosette forming cells and cell mediated immunity in ovarian cancer.

Parameters of cell mediated immunity were examined in 50 women with ovarian cancer, and included E-Rosette formation lymphocyte number, and lymphocyte blastogenesis to PPD. Alterations in these parameters were also determined following surgery and during chemotherapy. Relapse patients demonstrated significantly decreased numbers of "active" and "total" E-Rosette forming cells, as well as a significantly decreased spontaneous incorporation of 125Iododeoxyuridine into unstimulated lymphocytes; PPD responses and total lymphocyte counts were not significantly different from the control group. Analysis of T-cell subpopulations in relapse patients suggested that these cells were suppressed in the unseparated lymphocyte state. Chemotherapy led to an expected decrease in lymphocytes but an unexpected increase in the numbers of E-Rosette forming cells initially. It was postulated that serum factors accounted for the decreased values of these cells in relapse patients rather than a true depletion.

Erythrocytes↗
PubMed1979

Malignant change in benign cystic teratoma of the ovary.

In a clinico-pathological study of malignant disease of the ovary in the former North East Metropolitan Region, malignant transformation of benign cystic teratoma has emerged as the commonest malignancy of "germ cell" origin. The clinical and pathological details of 12 patients are reported.

Adult↗
PubMed1978

Ovarian cancer.

Explore the source record for details and available documents.

Alkylating Agents↗